| Ticker Details |
Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.
|
| IPO Date: |
November 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.19B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.64 | 2.79%
|
| Avg Daily Range (30 D): |
$0.68 | 1.49%
|
| Avg Daily Range (90 D): |
$0.81 | 2.06%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.47M |
| Avg Daily Volume (30 D): |
.35M |
| Avg Daily Volume (90 D): |
.43M |
| Trade Size |
| Avg Trade Size (Sh.): |
94 |
| Avg Trade Size (Sh.) (30 D): |
46 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Institutional Trades: |
3,289 |
| Avg Institutional Trade: |
$2.54M |
| Avg Institutional Trade (30 D): |
$2.83M |
| Avg Institutional Trade (90 D): |
$3.33M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.08M |
| Avg Closing Trade (30 D): |
$4.29M |
| Avg Closing Trade (90 D): |
$4.74M |
| Avg Closing Volume: |
91.67K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$.48
|
$.04
|
$-.12
|
|
Diluted EPS
|
$.47
|
$.04
|
$-.12
|
|
Revenue
|
$306.3M
|
$77.46M
|
$68.43M
|
|
Gross Profit
|
$228.38M
|
$56.4M
|
$49.27M
|
|
Net Income / Loss
|
$24.22M
|
$2.21M
|
$-6.3M
|
|
Operating Income / Loss
|
$18.24M
|
$.43M
|
$-8.06M
|
|
Cost of Revenue
|
$77.92M
|
$21.06M
|
$19.16M
|
|
Net Cash Flow
|
$44.83M
|
$16.06M
|
$9.2M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 16, 2013
|
1:20
|
|
Feb 18, 2010
|
1:8
|
|
|
|
